Compare Amphastar Pharmaceuticals Inc (AMPH) vs Duolingo Inc (DUOL) Price & Performance

AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.

The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.

Duolingo stock trades at $124.76, down 3.99% on the day, as the language learning platform shows strong fundamental performance with revenue reaching $1.04 billion in 2025 and net income of $414 million. The company has consistently beaten earnings expectations in recent quarters, with technical indicators showing a bullish trend despite some overbought signals. Recent news highlights AI integration improvements and user growth potential, with the stock trading above analyst consensus price targets.

Duolingo presents a compelling growth story with robust profitability metrics and expanding user base, though valuation remains elevated. Key risks include AI disruption concerns and competitive pressures in the edtech space. The current price offers potential upside to high analyst targets but requires monitoring of user growth sustainability and margin trends.